Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14904334 | 0.74 | FYN (0.34) | HTTALDH1A1RAB9AL3MBTL1KMT2A | |
| Anthracene SCHEMBL28443236 | 0.58 | ALDH1A1 (0.56) | HSD17B10CASP1ALDH1A1RAB9ATDP1 | |
| SCHEMBL29266808 | 0.58 | ALDH1A1 (0.56) | KDM4EHSD17B10HTTALDH1A1RAB9A | |
| SCHEMBL481505 | 0.58 | ALDH1A1 (0.75) | HSD17B10ALDH1A1RAB9ATDP1KMT2A | |
| SCHEMBL8452262 | 0.58 | ALDH1A1 (0.75) | HSD17B10ALDH1A1RAB9ATDP1KMT2A | |
| SCHEMBL4332773 | 0.58 | ALDH1A1 (0.75) | HSD17B10ALDH1A1RAB9ATDP1KMT2A | |
| Methylamine SCHEMBL28202149 | 0.57 | ALDH1A1 (0.47) | KDM4EHSD17B10HTTALDH1A1RAB9A | |
| SCHEMBL1836101 | 0.57 | HSD17B10 (0.41) | KDM4EHSD17B10CASP1HTTRAB9A | |
| SCHEMBL2008748 | 0.57 | PARP1 (0.50) | KDM4EALDH1A1RAB9AKMT2A | |
| SCHEMBL30992115 | 0.57 | ALDH1A1 (0.53) | KDM4EHSD17B10HTTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102617-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | RPS4X, RPS4Y1, MRPL21 | KDM4E 2209/4885HSD17B10 3692/4885CASP1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.